Lawsuits allege Tepezza — the first drug approved for thyroid eye disease — causes permanent hearing loss and tinnitus, and that patients were not warned of the risk until years after approval.
Tepezza (teprotumumab) was approved in 2020 as the first treatment for thyroid eye disease. It is delivered through a series of IV infusions over several months.
After approval, patients and studies reported hearing loss, tinnitus, muffled hearing, and autophony — some permanent. A warning about hearing impairment was not added to the label until 2023. Lawsuits allege the manufacturer knew or should have known of ototoxicity risk from clinical data but failed to warn.
Federal claims are consolidated in a multidistrict litigation in the Northern District of Illinois (MDL 3079), which continues to grow as more patients connect persistent hearing problems to their infusions.
MDL 3079 in the Northern District of Illinois is active with hundreds of pending cases. Coordinated pretrial proceedings are underway — no global settlement has been announced.
Qualification criteria change as litigation develops. The only way to know whether your experience may fit the current criteria is a review.
The Tepezza campaign is pre-selected below. Tell us what happened — a specialist will review whether your information may fit the current criteria.
You are reviewing: Tepezza Claims. Complete the form — a case specialist may follow up if your information appears to fit.
Attorney advertising. The Torts Attorney provides legal marketing and case-acquisition services and is not a law firm. Submitting this form does not create an attorney-client relationship and does not guarantee review, acceptance, or any outcome. Prior results do not guarantee similar outcomes.